In a recent issue of the journal Diabetes Care, Peter Butler, MD, of the University of California Los Angeles weighs in on recent research showing a potential link between certain diabetes drugs and an inflammation of the cancer called pancreatitis, as well as pancreatic cancer.
Butler himself was lead researcher for a study published in the journal Gastroenterology, which reported higher rates of pancreatitis and pancreatic cancer in patients taking the ...
continue reading...
A news release from Johns Hopkins goes into detail about a study, led by one of the institution’s researchers, which concluded that people taking the diabetes medications Byetta and Januvia are twice as likely to be hospitalized with pancreatitis.
Pancreatitis is an inflammation of the pancreas that’s often a precursor to pancreatic cancer.
Results of the study were published online in the medical journal JAMA Internal Medicine. Researchers concluded that sitagliptin and ...
continue reading...
A new study by Canadian researchers adds to a growing pool of evidence that Lipitor and other types of cholesterol-lowering drugs called statins put patients at a higher risk of developing diabetes.
According to a story on CTV News, researchers published the results of their study in BMJ, a journal of the British Medication Association.
The story notes that previous research has spotlighted a possible link between taking some statins and diabetes, ...
continue reading...
According to Reuters, Merck’s quarterly sales of diabetes drug Januvia – the company’s biggest product – took a nosedive in quarterly sales, which has investors concerned.
Overall, shares of the company fell 1.6 percent to $46.23 for the quarter. Though the company’s profit beat forecasts for the quarter, the Reuters story attributes that largely to a favorable tax rate.
Januvia has been the subject of some health concerns recently. Studies have linked ...
continue reading...
A story on HispanicBusiness.com says pharmaceutical companies Merck and Pfizer, ordinarily rivals, are teaming up to develop a new medicine for type 2 diabetes.
Merck is paying $60 million up front for the rights to co-develop Pfizer’s diabetes drug called ertugliflozin, which is currently in late-stage development. Merck will also get the right to market ertugliflozin separately or in combination with its own diabetes treatment.
But recent health concerns have cropped up ...
continue reading...
According to an NBC News blog, the discovery of a new hormone that makes the cells destroyed by diabetes has enormous potential for treating the disease.
The story says nearly 26 million Americans have diabetes, according to the Centers for Disease Control and Prevention. In both type 1 and some cases of type 2 diabetes, patients have to inject insulin when they eat to make sure the body metabolizes the food ...
continue reading...
